Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04710303
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-09-28
First Post:
2021-01-13
Brief Title:
COVID-19 Vaccination Using a 2nd Generation E1E2BE3-Deleted Adenoviral Platform in Healthy South African Adults
Sponsor:
ImmunityBio Inc
Organization:
ImmunityBio Inc
Study Overview
Official Title:
Phase 1b Open-Label Study of the Safety Reactogenicity and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation E1E2BE3-Deleted Adenoviral Platform in Healthy South African Adults ProVIVA-SA-1
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1b open-label study in adult healthy participants This clinical trial is designed to assess the safety reactogenicity and immunogenicity of the hAd5-S-FusionN-ETSD vaccine and select a dose for future studies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None